Cargando…

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

OBJECTIVE: To demonstrate pharmacokinetic equivalence of CT-P10 and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA) with inadequate responses or intolerances to antitumour necrosis factor agents. METHODS: In this randomised phase I trial, patients with active RA were randomly as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoo, Dae Hyun, Suh, Chang-Hee, Shim, Seung Cheol, Jeka, Slawomir, Cons-Molina, Francisco Fidencio, Hrycaj, Pawel, Wiland, Piotr, Lee, Eun Young, Medina-Rodriguez, Francisco G, Shesternya, Pavel, Radominski, Sebastiao, Stanislav, Marina, Kovalenko, Volodymyr, Sheen, Dong Hyuk, Myasoutova, Leysan, Lim, Mie Jin, Choe, Jung-Yoon, Lee, Sang Joon, Lee, Sung Young, Kwon, Taek Sang, Park, Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446025/ https://www.ncbi.nlm.nih.gov/pubmed/27624791 http://dx.doi.org/10.1136/annrheumdis-2016-209540

Ejemplares similares

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial
por: Yoo, Dae Hyun, et al.
Publicado: (2017)

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis
por: Park, Won, et al.
Publicado: (2017)

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial
por: Shim, Seung Cheol, et al.
Publicado: (2019)

Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial
por: Park, Won, et al.
Publicado: (2018)

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial
por: Suh, Chang-Hee, et al.
Publicado: (2019)

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
por: Park, Won, et al.
Publicado: (2013)

Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies
por: Ahn, Ga Young, et al.
Publicado: (2020)

Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis
por: Iwaszko, Milena, et al.
Publicado: (2018)

Addendum: Iwaszko et al., Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes 2018, 9, 64
por: Iwaszko, Milena, et al.
Publicado: (2018)

Rituximab Treatment for Idiopathic Hypertrophic Pachymeningitis
por: Jang, Yoonhyuk, et al.
Publicado: (2017)

Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial
por: Westhovens, Rene, et al.
Publicado: (2020)

Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus
por: Bang, So-Young, et al.
Publicado: (2012)

Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
por: Kwon, Hyeok Chan, et al.
Publicado: (2020)

Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients
por: Song, Ahreum, et al.
Publicado: (2022)

Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis
por: Iwaszko, Milena, et al.
Publicado: (2020)

Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20
por: Lee, Sang Min, et al.
Publicado: (2023)

Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone
por: Shin, Junghoon, et al.
Publicado: (2017)

The rheumatoid hand in the light of fluorescence: a diagnostic technique of the future?
por: Żuchowski, Paweł, et al.
Publicado: (2019)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Surveillance and Control of Rubella in the Republic of Korea From 2001 to 2009: The Necessity for Enhanced Surveillance to Monitor Congenital Rubella Syndrome
por: Choe, Young June, et al.
Publicado: (2010)

Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
por: Burmester, Gerd, et al.
Publicado: (2020)

Concurrent treatment with rituximab and plasma exchange for severe refractory granulomatosis with polyangiitis: A case report
por: Song, Ran, et al.
Publicado: (2019)

Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
por: Kucharz, Eugeniusz J., et al.
Publicado: (2018)

Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy
por: Lee, Yuna, et al.
Publicado: (2006)

Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group
por: Song, Young Hae, et al.
Publicado: (2012)

Successful treatment with rituximab for central nervous system vasculitis caused by Epstein-Barr virus-associated lymphoproliferative disorder with immunoglobulin M gammopathy
por: Lee, Juhee, et al.
Publicado: (2022)

The changing role of ultrasonography examination in patients with rheumatoid arthritis in light of recent studies
por: Dura, Marta, et al.
Publicado: (2020)

The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
por: Góralczyk, Alicja, et al.
Publicado: (2020)

Wegener's Granulomatosis Presenting with Pachymeningitis: Clinical and Imaging Remission by Rituximab
por: Just, Søren Andreas, et al.
Publicado: (2011)

Rituximab-Induced Coronary Vasospasm
por: Lee, Linda, et al.
Publicado: (2012)

Comparison of the conventional Henry approach and trans-flexor carpi radialis approach for the treatment of distal radius fracture: A retrospective cohort study
por: Shim, Bum-Jin, et al.
Publicado: (2022)

Direct brain involvement of Takayasu arteritis treated with rituximab and infliximab: a case report
por: Kim, Seondeuk, et al.
Publicado: (2022)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Gene Expression Profile of T-cell Receptors in the Synovium, Peripheral Blood, and Thymus during the Initial Phase of Collagen-induced Arthritis
por: Kim, Ji-Young, et al.
Publicado: (2011)

Complications Following Burr Hole Craniostomy and Closed-System Drainage for Subdural Lesions
por: Lee, Hyun Seok, et al.
Publicado: (2018)

Refractory Epidermolysis Bullosa Acquisita with Chronic Graft-versus-Host Disease Successfully Treated with Rituximab
por: Han, Ju Hee, et al.
Publicado: (2023)

Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era
por: Song, Ga-Young, et al.
Publicado: (2020)

Autoimmune limbic encephalitis combined with leptomeningeal metastases of non-small cell lung cancer: treatment response to osimertinib, immunoglobulin, rituximab, and tocilizumab
por: Lee, Seolah, et al.
Publicado: (2023)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Acute kidney injury in pediatric patients with rhabdomyolysis
por: Lim, Young Shin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8trcigrcl1b3mn3b7njv1vjf09